New York State Common Retirement Fund lessened its stake in EXACT Sciences Co. (NASDAQ:EXAS) by 84.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 504,003 shares of the medical research company’s stock after selling 2,731,676 shares during the quarter. New York State Common Retirement Fund’s holdings in EXACT Sciences were worth $43,657,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. First Hawaiian Bank raised its stake in shares of EXACT Sciences by 160.0% in the 1st quarter. First Hawaiian Bank now owns 325 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 200 shares in the last quarter. Buffington Mohr McNeal acquired a new stake in shares of EXACT Sciences in the 1st quarter valued at about $30,000. Karp Capital Management Corp acquired a new stake in shares of EXACT Sciences in the 4th quarter valued at about $38,000. Shine Investment Advisory Services Inc. raised its stake in shares of EXACT Sciences by 130.2% in the 1st quarter. Shine Investment Advisory Services Inc. now owns 442 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 250 shares in the last quarter. Finally, CWM LLC raised its stake in shares of EXACT Sciences by 777.1% in the 4th quarter. CWM LLC now owns 614 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 544 shares in the last quarter.

In other EXACT Sciences news, Director Katherine S. Zanotti sold 25,000 shares of the company’s stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $92.81, for a total value of $2,320,250.00. Following the completion of the transaction, the director now owns 94,274 shares in the company, valued at approximately $8,749,569.94. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Jeffrey Thomas Elliott sold 2,447 shares of the company’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $93.20, for a total transaction of $228,060.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,201 shares of company stock worth $5,543,493. 3.20% of the stock is owned by company insiders.

EXAS opened at $94.00 on Friday. The stock has a market cap of $12.52 billion, a P/E ratio of -69.12 and a beta of 1.84. EXACT Sciences Co. has a fifty-two week low of $47.78 and a fifty-two week high of $105.28. The company has a current ratio of 8.39, a quick ratio of 8.13 and a debt-to-equity ratio of 1.02.

EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.01). The business had revenue of $162.00 million for the quarter, compared to analyst estimates of $153.07 million. EXACT Sciences had a negative return on equity of 28.83% and a negative net margin of 41.58%. EXACT Sciences’s revenue was up 79.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.33) EPS. Sell-side analysts predict that EXACT Sciences Co. will post -2.13 earnings per share for the current fiscal year.

EXAS has been the topic of a number of recent analyst reports. UBS Group upped their target price on shares of EXACT Sciences from $100.00 to $109.00 and gave the company a “buy” rating in a research note on Monday, January 28th. Craig Hallum restated a “buy” rating and issued a $115.00 target price (up previously from $95.00) on shares of EXACT Sciences in a research note on Wednesday, May 1st. BidaskClub lowered shares of EXACT Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 15th. Goldman Sachs Group upgraded shares of EXACT Sciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $85.00 to $120.00 in a research note on Tuesday, February 26th. Finally, Robert W. Baird upped their target price on shares of EXACT Sciences from $90.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, February 21st. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. EXACT Sciences presently has a consensus rating of “Buy” and an average price target of $108.45.

WARNING: “EXACT Sciences Co. (EXAS) Holdings Reduced by New York State Common Retirement Fund” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://theolympiareport.com/2019/05/24/exact-sciences-co-exas-holdings-reduced-by-new-york-state-common-retirement-fund.html.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

See Also: Asset Allocation

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.